Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa

SIMPLE SUMMARY: As the treatment advances, there were several novel agents developed for R/M HNSCC, including an anti-epidermal growth factor receptor antibody, cetuximab, and an anti-programmed death-1 immune checkpoint inhibitor, pembrolizumab and nivolumab. To date, little was known regarding the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chuan-Chien, Lien, Ching-Feng, Hwang, Tzer-Zen, Wang, Chih-Chun, Wang, Chien-Chung, Shih, Yu-Chen, Yeh, Shyh-An, Hsieh, Meng-Che
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139601/
https://www.ncbi.nlm.nih.gov/pubmed/35625956
http://dx.doi.org/10.3390/cancers14102351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139601/
https://www.ncbi.nlm.nih.gov/pubmed/35625956
http://dx.doi.org/10.3390/cancers14102351

Ejemplares similares